Literature DB >> 33946649

ACE2 Is an Adjacent Element of Atherosclerosis and COVID-19 Pathogenesis.

Anastasia V Poznyak1, Evgeny E Bezsonov2,3, Ali H Eid4,5, Tatyana V Popkova6, Ludmila V Nedosugova7, Antonina V Starodubova8,9, Alexander N Orekhov1,2,3.   

Abstract

COVID-19 is a highly contagious new infection caused by the single-stranded RNA Sars-CoV-2 virus. For the first time, this infection was recorded in December 2019 in the Chinese province of Wuhan. The virus presumably crossed the interspecies barrier and passed to humans from a bat. Initially, the disease was considered exclusively in the context of damage to the respiratory system, but it quickly became clear that the disease also entails serious consequences from various systems, including the cardiovascular system. Among these consequences are myocarditis, myocardial damage, subsequent heart failure, myocardial infarction, and Takotsubo syndrome. On the other hand, clinical data indicate that the presence of chronic diseases in a patient aggravates the course and outcome of coronavirus infection. In this context, the relationship between COVID-19 and atherosclerosis, a condition preceding cardiovascular disease and other disorders of the heart and blood vessels, is particularly interesting. The renin-angiotensin system is essential for the pathogenesis of both coronavirus disease and atherosclerosis. In particular, it has been shown that ACE2, an angiotensin-converting enzyme 2, plays a key role in Sars-CoV-2 infection due to its receptor activity. It is noteworthy that this enzyme is important for the normal functioning of the cardiovascular system. Disruptions in its production and functioning can lead to various disorders, including atherosclerosis.

Entities:  

Keywords:  ACE2; COVID-19; atherosclerosis; coronavirus disease

Mesh:

Substances:

Year:  2021        PMID: 33946649     DOI: 10.3390/ijms22094691

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  60 in total

Review 1.  Reassessing the Mechanisms of Acute Coronary Syndromes.

Authors:  Peter Libby; Gerard Pasterkamp; Filippo Crea; Ik-Kyung Jang
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

Review 2.  Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease.

Authors:  William Herrington; Ben Lacey; Paul Sherliker; Jane Armitage; Sarah Lewington
Journal:  Circ Res       Date:  2016-02-19       Impact factor: 17.367

Review 3.  Monocyte-Macrophages and T Cells in Atherosclerosis.

Authors:  Ira Tabas; Andrew H Lichtman
Journal:  Immunity       Date:  2017-10-17       Impact factor: 31.745

Review 4.  Inflammation, oxidative stress and renin angiotensin system in atherosclerosis.

Authors:  Kazim Husain; Wilfredo Hernandez; Rais A Ansari; Leon Ferder
Journal:  World J Biol Chem       Date:  2015-08-26

5.  Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease.

Authors:  Lidia Anguiano; Marta Riera; Julio Pascual; José Manuel Valdivielso; Clara Barrios; Angels Betriu; Sergi Clotet; Sergi Mojal; Elvira Fernández; María José Soler
Journal:  Atherosclerosis       Date:  2016-08-24       Impact factor: 5.162

6.  Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice.

Authors:  Rodrigo A Fraga-Silva; Fabrizio Montecucco; Fabiana P Costa-Fraga; Alessio Nencioni; Irene Caffa; Maiia E Bragina; François Mach; Mohan K Raizada; Robson A S Santos; Rafaela F da Silva; Nikolaos Stergiopulos
Journal:  Vascul Pharmacol       Date:  2015-08-22       Impact factor: 5.773

7.  Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality.

Authors:  Robert O Bonow; Gregg C Fonarow; Patrick T O'Gara; Clyde W Yancy
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

8.  Endothelial cell infection and endotheliitis in COVID-19.

Authors:  Zsuzsanna Varga; Andreas J Flammer; Peter Steiger; Martina Haberecker; Rea Andermatt; Annelies S Zinkernagel; Mandeep R Mehra; Reto A Schuepbach; Frank Ruschitzka; Holger Moch
Journal:  Lancet       Date:  2020-04-21       Impact factor: 79.321

Review 9.  The SARS-CoV-2 outbreak: What we know.

Authors:  Di Wu; Tiantian Wu; Qun Liu; Zhicong Yang
Journal:  Int J Infect Dis       Date:  2020-03-12       Impact factor: 3.623

10.  COVID-19 and its implications for thrombosis and anticoagulation.

Authors:  Jean M Connors; Jerrold H Levy
Journal:  Blood       Date:  2020-06-04       Impact factor: 25.476

View more
  4 in total

1.  A Differential Signature of Circulating miRNAs and Cytokines Between COVID-19 and Community-Acquired Pneumonia Uncovers Novel Physiopathological Mechanisms of COVID-19.

Authors:  Pedro Martínez-Fleta; Paula Vera-Tomé; María Jiménez-Fernández; Silvia Requena; Emilia Roy-Vallejo; Ancor Sanz-García; Marta Lozano-Prieto; Celia López-Sanz; Alicia Vara; Ángel Lancho-Sánchez; Enrique Martín-Gayo; Cecilia Muñoz-Calleja; Arantzazu Alfranca; Isidoro González-Álvaro; José María Galván-Román; Javier Aspa; Hortensia de la Fuente; Francisco Sánchez-Madrid
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

Review 2.  Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.

Authors:  Carlos A Labarrere; Ghassan S Kassab
Journal:  Front Immunol       Date:  2021-09-23       Impact factor: 7.561

Review 3.  Mechanisms of Cardiovascular System Injury Induced by COVID-19 in Elderly Patients With Cardiovascular History.

Authors:  Yaliu Yang; Mengwen Yan
Journal:  Front Cardiovasc Med       Date:  2022-05-04

4.  Risk for Subsequent SARS-CoV-2 Infection and Severe COVID-19 Among Community-Dwellers With Pre-Existing Cervicocephalic Atherosclerosis: A Population-Based Study.

Authors:  Oscar H Del Brutto; Robertino M Mera; Victor J Del Brutto; Bettsy Y Recalde; Denisse A Rumbea; Aldo F Costa; Mark J Sedler
Journal:  J Prim Care Community Health       Date:  2022 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.